entertainment -WSS

entertainment

author：leisure time 2025-09-27 19:49:59 - browse：9247

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Laying a path for careers in science

WSS

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Using force crossed my mind when examining a defiant young patient

Study suggests Covid rebound is far more common with Paxlovid than without

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Experimental asthma app from Apple and Anthem shows promise

explore

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

5 ways to address the shortage of health care workers

Malaria cases in Florida and Texas: Here’s what you need to know

Using force crossed my mind when examining a defiant young patient

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Neuroscience renaissance leads to new crop of psychiatric drugs

Medical leaders decry Supreme Court decision on affirmative action

Pfizer is about to make a big push in cancer. Will investors listen?

Wildfire smoke exposes gaps in outdoor worker protections

CDC advisory group OKs chikungunya vaccine

Wikipedia

Neuroscience renaissance leads to new crop of psychiatric drugs

Redefining sustainability for the pharmaceutical industry

STAT Madness 2024: Meet the contenders

FDA reorg will put new emphasis on investigations, sources say

FDA reorg will put new emphasis on investigations, sources say

Pfizer is about to make a big push in cancer. Will investors listen?

hotspot

hotspot

entertainment

entertainment